Expenditures of the overall statutory health insurances market for medicinal products, test diagnostics and vaccines amounted to EUR 25bn in the first nine months of 2012 – without any rebates on pharmacy sales prices. This is a plus of 0.9% compared to 2011 as information provider IMS Health revealed.
Here, neither the mandatory discount granted by pharmaceutical companies nor the discount granted by pharmacies has been subtracted. Both add up to EUR 3bn in the first nine months of 2012. Savings from rebate contracts and patient co-payments were not taken into account.
The number of packages prescribed remained stable (minus 0.1%). Prices declined slightly (minus 1.5%). Business volume declined by 3.5% in the reference price market. Business volume increased by 3.6% with regards to medicinal products without reference prices.
[ilink url=“http://www.pharmazeutische-zeitung.de/index.php?id=nachrichten&type=0&no_cache=1&Nachricht_ID=44349&Nachricht_Title=Nachrichten_GKV%3A+Nur+geringer+Ausgabenzuwachs“] Link zur Quelle (Pharmazeutische Zeitung)[/ilink]